AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22727500 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500mg b.i.d.)
Number of subjects: 74
Study 22727500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 19780875 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir plus Lamivudine (ADV/LAM)
Number of subjects: 60
Study 19780875 — intervention group
Group type: COMPARATOR
Intervention: Adefovir monotherapy (ADV)
Number of subjects: 60
Study 17335695 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolisa HCV Ag-Ab ULTRA
Number of subjects: 1693
Study 17335695 — intervention group
Group type: COMPARATOR
Intervention: Ortho HCV 3.0
Number of subjects: 1693
Study 15591724 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified mastectomy with adjuvant chemo- or radiation therapy
Number of subjects: 206
Study 15591724 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conserving surgery, lumpectomy and radiotherapy
Number of subjects: 206
Study 11887170 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 20
Study 11887170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9516652 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (n = 100)
Number of subjects: 182
Study 9516652 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued smoking, n = 82)
Number of subjects: 182
Study 9516652 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (n = 29 who fulfilled the study)
Number of subjects: 182
Study 9516652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (smoking cessation and control)
Number of subjects: 182
Study 8041896 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred treatment for glottic laryngeal cancer
Number of subjects: 1649
Study 8041896 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' specialty
Number of subjects: 1649
Study 8041896 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic location of practice
Number of subjects: 1649
Study 8041896 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment recommendations for patients vs self
Number of subjects: 1649
Study 3276390 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 months of chemotherapy according to a modified Rosen schedule
Number of subjects: 205
Study 3276390 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective bilateral lung irradiation of 20 Gy
Number of subjects: 205
Study 3276390 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of chemotherapy followed by lung irradiation
Number of subjects: 205
Study 3276390 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy arms
Number of subjects: 205
Study 3276390 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 205
Study 3276390 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher age or tibia localizations
Number of subjects: 205
Study 3276390 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy arms
Number of subjects: 205
Study 3276390 — intervention group
Group type: COMPARATOR
Intervention: Elective lung irradiation
Number of subjects: 205
Study 4278358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 40
Study 4278358 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 40
Study 4278358 — intervention group
Group type: COMPARATOR
Intervention: Sulphadimidine
Number of subjects: 40
Study 31492492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 9932
Study 31492492 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 9932
Study 26680684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 26680684 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide (250 mg)
Number of subjects: 15
Study 26680684 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (400 mg)
Number of subjects: 15
Study 26680684 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide (250 mg) with Aminophylline (400 mg)
Number of subjects: 15
Study 24291456 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly structured aerobic and resistance exercise intervention
Number of subjects: 150
Study 24291456 — intervention group
Group type: COMPARATOR
Intervention: Health education condition
Number of subjects: 150
Study 22951849 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 30
Study 22951849 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 30
Study 19833475 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-focused educational programs based on self-management (written and individualized action plan, self-monitoring, and regular medical review)
Number of subjects: 0
Study 19833475 — intervention group
Group type: COMPARATOR
Intervention: Simple provision of information about asthma
Number of subjects: 0
Study 17524860 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 microg/day) started in the donor 6 days before donation and continued in recipient for 6 months after transplantation.
Number of subjects: 10
Study 17524860 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppressive regimen (cyclosporine/mycophenolate mofetil and prednisolone).
Number of subjects: 10
Study 15073670 — intervention group
Group type: EXPERIMENTAL
Intervention: ZYC101a
Number of subjects: 127
Study 15073670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 11772295 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 11772295 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies aimed at eradicating chronic infections
Number of subjects: 0
Study 9340898 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO 160/120 (Sabal and Urtica extract)
Number of subjects: 543
Study 9340898 — intervention group
Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 543
Study 7880675 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline approach with flexed lateral position (ML)
Number of subjects: 100
Study 7880675 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline approach with sitting position (MS)
Number of subjects: 100
Study 7880675 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian approach with flexed lateral position (PL)
Number of subjects: 100
Study 7880675 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian approach with sitting position (PS)
Number of subjects: 100
Study 7880675 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexed sitting position
Number of subjects: 100
Study 7880675 — intervention group
Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 100
Study 2978875 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-1,6-diphosphate (FDP) 10 gm intravenously for three days
Number of subjects: 15
Study 2978875 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 15
Study 2144803 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 2144803 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 0
Study 2144803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1099032 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% urea cream
Number of subjects: 0
Study 1099032 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream with pH of 6
Number of subjects: 0
Study 31488402 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised hypertonic saline (HS) treatment (4 mL of 3% sodium chloride every 6 hours)
Number of subjects: 121
Study 31488402 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive care (SC)
Number of subjects: 121
Study 30885692 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV1‐PG9DP (4 × 10^12 to 1.2 × 10^14 vector genomes)
Number of subjects: 21
Study 30885692 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV1‐PG9DP
Number of subjects: 21
Study 30885692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 27815214 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg of propranolol
Number of subjects: 0
Study 27815214 — intervention group
Group type: COMPARATOR
Intervention: 40mg of placebo
Number of subjects: 0
Study 25534727 — intervention group
Group type: EXPERIMENTAL
Intervention: LFF571 (200 mg four times daily for 10 days)
Number of subjects: 72
Study 25534727 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (125 mg four times daily for 10 days)
Number of subjects: 72
Study 25534727 — intervention group
Group type: EXPERIMENTAL
Intervention: LFF571
Number of subjects: 72
Study 25534727 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 72
Study 23587029 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 7485
Study 23587029 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based treatment
Number of subjects: 7485
Study 23587029 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HDL < 1.21 mmol/l
Number of subjects: 7485
Study 21440948 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 21440948 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 21440948 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin and gemfibrozil
Number of subjects: 0
Study 21440948 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20186637 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness intervention (10 weekly interpersonal forgiveness therapy sessions)
Number of subjects: 32
Study 20186637 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (10 weekly sessions)
Number of subjects: 32
Study 17432640 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion (Group A)
Number of subjects: 41
Study 17432640 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus auricular point sticking (Group B)
Number of subjects: 41
Study 17432640 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture (Group C)
Number of subjects: 41
Study 15956126 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty (BA)
Number of subjects: 36
Study 15956126 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 36
Study 11550967 — intervention group
Group type: COMPARATOR
Intervention: Fas promoter -670 genotype (AA, GA, GG) in SLE patients
Number of subjects: 87
Study 11550967 — intervention group
Group type: COMPARATOR
Intervention: Fas promoter -670 genotype (AA, GA, GG) in RA patients
Number of subjects: 87
Study 11550967 — intervention group
Group type: COMPARATOR
Intervention: Fas promoter -670 genotype in second cohort of SLE patients (n = 85)
Number of subjects: 87
Study 9596021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive test performance in African‐American Alzheimer's disease patients
Number of subjects: 0
Study 9596021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive test performance in European‐American Alzheimer's disease patients
Number of subjects: 0
Study 7908357 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 bolus/c7E3 infusion
Number of subjects: 2099
Study 7908357 — intervention group
Group type: COMPARATOR
Intervention: c7E3 bolus/placebo infusion
Number of subjects: 2099
Study 3047338 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (1 mg/m2) and prednisone (0.6 mg/kg/d for seven days at 8-week intervals)
Number of subjects: 589
Study 3047338 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine and prednisone
Number of subjects: 589
Study 29226610 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating concentrations of phenylalanine
Number of subjects: 12671
Study 29226610 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating concentrations of acetate
Number of subjects: 12671
Study 29226610 — intervention group
Group type: COMPARATOR
Intervention: Model with established risk factors and NT-proBNP
Number of subjects: 12671
Study 29226610 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine in FINRISK 1997
Number of subjects: 12671
Study 26936139 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g high molecular weight (HMW) β‐glucan/d
Number of subjects: 30
Study 26936139 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g low molecular weight (LMW) β‐glucan/d
Number of subjects: 30
Study 26936139 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g low molecular weight (LMW) β‐glucan/d
Number of subjects: 30
Study 26936139 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 30
Study 24602973 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 81
Study 24602973 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 81
Study 22985900 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical analgesic patches
Number of subjects: 30
Study 22985900 — intervention group
Group type: COMPARATOR
Intervention: No drug patches (control)
Number of subjects: 30
Study 22985900 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity between left medial prefrontal cortex and bilateral insula
Number of subjects: 30
Study 22985900 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillations in left dorsolateral prefrontal cortex
Number of subjects: 30
Study 22985900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medial and lateral prefrontal functional connections
Number of subjects: 30
Study 20004553 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 582
Study 20004553 — intervention group
Group type: COMPARATOR
Intervention: Small-incision cholecystectomy
Number of subjects: 582
Study 18025650 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma agents
Number of subjects: 75
Study 18025650 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 75
Study 16334846 — intervention group
Group type: EXPERIMENTAL
Intervention: MR digital subtraction angiography (MR‐DSA)
Number of subjects: 12
Study 12030959 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC-omeprazole
Number of subjects: 150
Study 12030959 — intervention group
Group type: COMPARATOR
Intervention: OAC-placebo
Number of subjects: 150
Study 12030959 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful eradication
Number of subjects: 150
Study 12030959 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed eradication
Number of subjects: 150
Study 10687264 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy (amoxicillin at 500 mg twice a day for 14 days, metronidazole at 500 mg twice a day for 10 days, omeprazole at 20 mg twice a day for 20 days)
Number of subjects: 20
Study 10687264 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study 8914911 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 1:100,000
Number of subjects: 81
Study 8914911 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 1:200,000
Number of subjects: 81
Study 8914911 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 1:400,000
Number of subjects: 81
Study 8914911 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 1:800,000
Number of subjects: 81
Study 1991748 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nail avulsion
Number of subjects: 163
Study 1991748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail edge excision
Number of subjects: 163
Study 1991748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail edge excision with phenolisation of the germinal matrix
Number of subjects: 163
Study 1991748 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail edge excision and phenolisation
Number of subjects: 163
Study 6350408 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (M)
Number of subjects: 27
Study 6350408 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation with cold air (HV)
Number of subjects: 27
Study 6350408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative M PD20
Number of subjects: 27
Study 30070398 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy + Cognitive Behavioral Therapy (IRT + CBT)
Number of subjects: 42
Study 30070398 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) alone
Number of subjects: 42
Study 26991889 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise augmentation of treatment as usual (part of STRIDE trial)
Number of subjects: 302
Study 26991889 — intervention group
Group type: COMPARATOR
Intervention: Cocaine use disorder
Number of subjects: 302
Study 26991889 — intervention group
Group type: COMPARATOR
Intervention: Cocaine plus other stimulant use disorders
Number of subjects: 302
Study 25077835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation
Number of subjects: 114
Study 25077835 — intervention group
Group type: COMPARATOR
Intervention: Contact lens
Number of subjects: 114
Study 22353759 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 61
Study 22353759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20799973 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted community-based care program including facilitated bone mineral density testing, patient education, and patient-specific recommendations for osteoporosis treatment.
Number of subjects: 201
Study 20799973 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted community-based care program
Number of subjects: 201
Study 17608331 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFlex system (dynamic stabilization with or without PLIF)
Number of subjects: 103
Study 17608331 — intervention group
Group type: COMPARATOR
Intervention: PLIF + BioFlex system (rigid fixation)
Number of subjects: 103
Study 17608331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol memory loops implanted
Number of subjects: 103
Study 16273666 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (50.4 Gy, 1.8 Gy per fraction plus bolus 5-fluorouracil and leucovorin) followed by surgery after 4-6 weeks
Number of subjects: 316
Study 16273666 — intervention group
Group type: COMPARATOR
Intervention: Short-course irradiation (5 x 5 Gy) followed by surgery within 7 days
Number of subjects: 316
Study 12212870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare toothbrush
Number of subjects: 50
Study 12212870 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 50
Study 10540368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular stent placement
Number of subjects: 17
Study 7573781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of ethanol (0.5 g/kg)
Number of subjects: 10
Study 7573781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2333581 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with vincristine, daunorubicin, prednisone, cytosine arabinoside, and 6-thioguanine; followed by consolidation treatment with VM-26, cyclophosphamide, BCNU, and L-asparaginase; CNS prophylaxis with intrathecal methotrexate.
Number of subjects: 43
Study 2333581 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT) in the first complete remission (CR) for patients under 45 years with HLA identical sibs.
Number of subjects: 43
Study 2333581 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous BMT for patients without HLA-identical sibs.
Number of subjects: 43
Study 2333581 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy for remaining patients.
Number of subjects: 43
Study 2333581 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment including chemotherapy and BMT.
Number of subjects: 43
Study 444025 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief hospitalization followed by day care
Number of subjects: 175
Study 444025 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief hospitalization without day care
Number of subjects: 175
Study 444025 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient care
Number of subjects: 175
Study 31993719 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate
Number of subjects: 147
Study 31993719 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 147
Study 31993719 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 147
Study 30663076 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab at week 6
Number of subjects: 693
Study 30663076 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab concentrations at weeks 6, 14, and steady state
Number of subjects: 693
Study 28942450 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 90
Study 28942450 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 90
Study 23835670 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 60
Study 23835670 — intervention group
Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 60
Study 24039459 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of methylphenidate (MPH)
Number of subjects: 21
Study 24039459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 21358384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 83
Study 21358384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 83
Study 21358384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 19465470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready‐to‐use fortified spread
Number of subjects: 491
Study 19465470 — intervention group
Group type: COMPARATOR
Intervention: Corn‐soy blend
Number of subjects: 491
Study 17557044 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapies (endoscopic mucosal resection, ablative therapies)
Number of subjects: 0
Study 17557044 — intervention group
Group type: COMPARATOR
Intervention: Screening and surveillance strategies
Number of subjects: 0
Study 17557044 — intervention group
Group type: COMPARATOR
Intervention: Risk stratification
Number of subjects: 0